ANEW ETF

Profile

Name:

ProShares MSCI Transformational Changes ETF

Assets under management:

$8 M

Expense ratio:

0.45%

Inception date:

16 October 2020

Last ex-dividend date:

25 September 2024

Next ex-dividend date:

N/A

Description:

ANEW ETF is an exchange-traded fund that focuses on companies involved in sustainable and renewable energy. It aims to provide investors with exposure to the growing green economy, promoting environmentally friendly practices while seeking long-term capital appreciation.
Name
Weight
DE logo
Deere(DE)
2.33 %
NINTENDO CO LTD(7974)
2.20 %
CTVA logo
Corteva(CTVA)
2.10 %
ABBV logo
AbbVie(ABBV)
2.09 %
NFLX logo
Netflix(NFLX)
2.08 %
AAPL logo
Apple(AAPL)
2.05 %
2.02 %
DASH logo
DoorDash(DASH)
2.00 %

Holding types

Countries

Sectors

Analyst ratings

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
ANEW
prismmediawire.com17 September 2024

Strategic Rebranding Reflects Focus on Neurodegenerative Therapies and Healthy Longevity New York, NY, September 17, 2024 – PRISM MediaWire – The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ: KLTO), and has launched a new website, www.klothoneuro.com.

ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
ANEW
globenewswire.com17 September 2024

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC.

Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
ANEW
prismmediawire.com04 September 2024

Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 – PRISM MediaWire – ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development.

Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
ANEW
globenewswire.com04 September 2024

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC.

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW
prismmediawire.com26 August 2024

Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 – ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors.

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
ANEW
globenewswire.com26 August 2024

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors.

ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
ANEW
prismmediawire.com21 August 2024

New York, NY. August 21, 2024 – ANEW MEDICAL, INC.

ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
ANEW
globenewswire.com21 August 2024

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or the “Company”) (Nasdaq: WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke (“TTS”) regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines.

ANEW MEDICAL, INC. Appoints New CFO
ANEW MEDICAL, INC. Appoints New CFO
ANEW MEDICAL, INC. Appoints New CFO
ANEW
prismmediawire.com19 August 2024

New York, NY, August 19, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.

ANEW MEDICAL, INC. Appoints New CFO
ANEW MEDICAL, INC. Appoints New CFO
ANEW MEDICAL, INC. Appoints New CFO
ANEW
globenewswire.com19 August 2024

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company's Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is ANEW ETF?
  • Does ANEW pay dividends?
  • What stocks are in ANEW ETF?
  • What is the current assets under management for ANEW?
  • What is ANEW average volume?
  • What is ANEW expense ratio?
  • What is ANEW inception date?

What is ANEW ETF?

ANEW ETF is an exchange-traded fund that focuses on companies involved in sustainable and renewable energy. It aims to provide investors with exposure to the growing green economy, promoting environmentally friendly practices while seeking long-term capital appreciation.

Does ANEW pay dividends?

Yes, the ProShares MSCI Transformational Changes ETF does pays dividends, with the most recent payment being $0.03 per share. The last ex-dividend date was on 25 September 2024, and the next ex-dividend date has not been announced yet

What stocks are in ANEW ETF?

As of today, ProShares MSCI Transformational Changes ETF inlcudes 147 holdings, with 124 of them being companies from 16 different countries and 9 sectors. The most weighted holdings are Deere (2.33%), NINTENDO CO LTD (2.2%) and Corteva (2.1%)

What is the current assets under management for ANEW?

Assets under management of ProShares MSCI Transformational Changes ETF is $8 M

What is ANEW average volume?

Average volume of ProShares MSCI Transformational Changes ETF is $356

What is ANEW expense ratio?

Expense ratio of ProShares MSCI Transformational Changes ETF is 0.45%

What is ANEW inception date?

Inception date of ProShares MSCI Transformational Changes ETF is 16 October 2020